Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) cleared Opdivo (nivolumab) for use with platinum-based chemo to reduce the size ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Bristol Myers Squibb (BMY) closed at $54.20 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0 ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...

A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...